Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Verizon Communications Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B), while Verizon Communications Inc trades at $43.76 (market cap $181.64B). The key difference: Verizon Communications Inc is the larger of the two by market cap, and Verizon Communications Inc pays a 6.51% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | VZ | |
|---|---|---|
Market Cap | $121.95B | $181.64B |
Sector | Health | Media |
52-Week High | $529.59 | $51.38 |
52-Week Low | $366.54 | $38.40 |
Enterprise Value | $116.69B | $369.14B |
Volume | — | 22,584,735 |
Dividend Yield | — | 6.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Verizon (VZ) trades at $43.78, up 0.44% today, with a bearish technical signal but strong fundamentals including a P/E of 10.61 and consistent earnings beats. Recent news highlights a restructuring involving 3,000 job cuts and the sale of 274 stores to franchisees, aimed at boosting efficiency ahead of Q2 2026 earnings. Cash flow improved in 2025 with net cash flow of $14.9 billion, supporting its 6.5% dividend yield.
Outlook: Attractive for income investors due to stable cash flows and high dividend, but faces risks from 5G competition and margin pressure. Analyst consensus price target is $47.83, suggesting upside potential if execution improves. Key risks include debt levels and industry discounts threatening profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
